(Q38091377)

28 August 2017

title

Cardiac toxicity of anticancer agents (English)

1 reference

28 August 2017

3

Marta Beggiato

1 reference

28 August 2017

Alessandro Colombo

1

1 reference

28 August 2017

Carlo Cipolla

series ordinal

2

1 reference

28 August 2017

Daniela Cardinale

series ordinal

4

1 reference

28 August 2017

publication date

1 May 2013

1 reference

Current cardiology reports

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

362

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-013-0362-6

28 August 2017

exact match

0 references

cites work

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

The prevention and management of cardiovascular complications of chemotherapy in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Molecular and cellular mechanisms of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Contrast administration reduces interobserver variability in determination of left ventricular ejection fraction in patients with left ventricular dysfunction and good baseline endocardial border delineation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

The clinical applications of contrast echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Assessment of left ventricular function by real-time 3-dimensional echocardiography compared with conventional noninvasive methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Alterations of left ventricular myocardial characteristics associated with obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Global longitudinal strain in relation to the severity of aortic stenosis: a two-dimensional speckle-tracking study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Left ventricular contraction-relaxation coupling in normal, hypertrophic, and failing myocardium quantified by speckle-tracking global strain and strain rate imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Magnetic resonance imaging detects significant sex differences in human myocardial strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Role of MRI in clinical cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiovascular magnetic resonance imaging: current and emerging applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Breast cancer therapies and cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Role and importance of biochemical markers in clinical cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Mechanism of troponin elevations in patients with acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Role of biomarkers in chemotherapy-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Third Universal Definition of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Myocardial Dysfunction Late After Low-Dose Anthracycline Treatment in Asymptomatic Pediatric Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-013-0362-6

Live/real time three-dimensional transthoracic echocardiographic assessment of left ventricular volumes, ejection fraction, and mass compared with magnetic resonance imaging

21 January 2018

1 reference

12 December 2020

Comparison of two- and three-dimensional echocardiography with sequential magnetic resonance imaging for evaluating left ventricular volume and ejection fraction over time in patients with healed myocardial infarction

1 reference

12 December 2020

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

12 December 2020

Cardiotoxicity due to cancer therapy.

1 reference

12 December 2020

Cardiac troponins--biochemical markers of cardiac toxicity after cytostatic therapy

1 reference

12 December 2020

Cancer drugs and the heart: importance and management

1 reference

12 December 2020

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated

1 reference

12 December 2020

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

1 reference

12 December 2020

Chemotherapy-induced cardiotoxicity: role of the conventional echocardiography and the tissue Doppler

1 reference

12 December 2020

Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity?

1 reference

12 December 2020

Heart of darkness: the downside of trastuzumab

1 reference

12 December 2020

Cardiac mechanisms underlying normal exercise tolerance: gender impact

1 reference

12 December 2020

Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy

1 reference

12 December 2020

Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction

1 reference

12 December 2020

Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines

1 reference

12 December 2020

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

12 December 2020

cTnT can be a useful marker for early detection of anthracycline cardiotoxicity

1 reference

12 December 2020

Assessment of regional longitudinal myocardial strain rate derived from doppler myocardial imaging indexes in normal and infarcted myocardium

1 reference

12 December 2020

Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

10.1007/S11886-013-0362-6

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1005041869

0 references

1 reference